多巴胺药物对帕金森病中抑郁症症状尺寸的分离效应
Harry Costello1, Anette-Eleonore Schrag2, Robert Howard3
1Institute of Cognitive Neuroscience, University College London, London, UK.
Nature. Mental health
|August 12, 2024
概括
多巴胺激动剂有效地治疗帕金森病 (PD) 中的动机抑郁症. 单胺氧化酶-B 抑制剂对抑郁症和动机症状都有好处,在晚期神经退行症中,动机改善会减弱.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 精神病学是一个精神病学.
背景情况:
- 抑郁症是帕金森病 (PD) 的常见和致残的非运动症状.
- 抑郁症的动机症状在PD中特别普遍,与条状多巴胺基缩有关.
- 标准抗抑郁药通常对PD中的抑郁症无效.
研究的目的:
- 研究多巴胺作用药物对帕金森病中不同抑郁症症状尺寸的差异性影响.
- 为了确定特定的抗帕金森症药物是否对激励和一般抑郁症状有不同的影响.
主要方法:
- 对412名新诊断的帕金森病患者的5年纵向研究数据的分析.
- 使用15项老年抑郁量表来得出"动机"和"抑郁症"症状尺寸.
- 使用序列多巴胺转运器成像评估条状多巴胺基神经退行.
主要成果:
- 在PD中确定了多巴胺类药物和特定抑郁症维度之间的可分离关联.
- 多巴胺激动剂在治疗抑郁症的动机症状方面表现出有效性.
- 单胺氧化酶-B 抑制剂改善了抑郁和动机症状,尽管在晚期神经退行症中,动机效益减少了.
结论:
- 多巴胺类药物选择可以根据帕金森病的特定抑郁症症状尺寸进行定制.
- 多巴胺激动剂对于PD抑郁症的动机缺陷特别有效.
- 单胺氧化酶-B 抑制剂提供更广泛的益处,但它们对动机的影响可能因疾病严重程度而受到限制.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Depressive Disorders: MDD and Dysthymia
71
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
71
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
290
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
290


